Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).
Alsheikh-Ali
Alawi A
AA
Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Boston, Massachusetts 02111, USA.
Abourjaily
Heather M
HM
Karas
Richard H
RH
D020909:Acarbose / Q000009:adverse effects; D016907:Adverse Drug Reaction Reporting Systems; D000924:Anticholesteremic Agents / Q000009:adverse effects; D000069059:Atorvastatin; D002839:Chromans / Q000009:adverse effects*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007328:Insulin / Q000009:adverse effects; D008297:Male; D008687:Metformin / Q000009:adverse effects; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects*; D019821:Simvastatin / Q000009:adverse effects; D013453:Sulfonylurea Compounds / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects*; D045162:Thiazolidinediones; D000077288:Troglitazone
D000924:Anticholesteremic Agents; D002839:Chromans; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D011758:Pyrroles; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; D000069059:Atorvastatin; C089946:2,4-thiazolidinedione; D019821:Simvastatin; D000077288:Troglitazone; D020909:Acarbose